CN1171957A - Drug for curing coronary disease - Google Patents
Drug for curing coronary disease Download PDFInfo
- Publication number
- CN1171957A CN1171957A CN 97111879 CN97111879A CN1171957A CN 1171957 A CN1171957 A CN 1171957A CN 97111879 CN97111879 CN 97111879 CN 97111879 A CN97111879 A CN 97111879A CN 1171957 A CN1171957 A CN 1171957A
- Authority
- CN
- China
- Prior art keywords
- medicine
- rhizoma chuanxiong
- radix ginseng
- present
- myocardial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Chinese medicine for curing coronary heart disease, angina pectoris and cardiac infarction with good curative effect. Said medicine preparation is made up by using ginseng and ligusticum wallichii root through a certain preparation process.
Description
The present invention relates to a kind of Chinese patent medicine for the treatment of coronary heart disease, is to be effective ingredient with the Chinese herbal medicine specifically, and the medicine according to special process is prepared from has better curative effect to coronary heart disease, angina pectoris, myocardial infarction.
Coronary heart disease is commonly encountered diseases, frequently-occurring disease, also is the major reason of crowd's death, has carried out extensive, deep research both at home and abroad, has obtained remarkable progress in recent years, but still have more problem aspect treatment, has to be solved.Motherland's medical science has abundant theory and treatment experience in preventing and treating the thoracic obstruction, pained, all kinds of coronary heart disease, obtained better curative effect.For development based on inheritance motherland medicine and pharmacology legacy, performance Chinese medicine advantage, guarantee population health, we are on the basis of clinical practice for many years, this problem has been carried out deep research, through screening and experimentation, a kind of treatment coronary heart disease, angina pectoris, myocardial infarction medicine have been invented to multiple Chinese herbal medicine.
Therefore, the object of the invention provides a kind of medicine for the treatment of coronary heart disease, angina pectoris, myocardial infarction.
The coronary heart disease most of patients, much more deficiency in origin and excess in superficiality belongs to the syndrome of blood stasis due to qi deficiency person and to see.The inventor is according to theory of Chinese medical science, clinical practice for many years and this year achievement in research, successively 35 kinds of blood-activating and stasis-removing have been carried out systematic study, therefrom select medicine and ginseng compatibility preferably such as Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, carried out the comparative study of many indexs, the confirmer participates in the Rhizoma Chuanxiong compatibility and is better than other combinations as a result, on this basis, carried out Preliminary Clinical Observation again, confirmed not only good effect of this medicine, and have the advantage for the treatment of both the principal and secondary aspects of a disease, to the coronary heart disease determined curative effect of blood stasis due to qi deficiency, be better than other similar medicines.
Therefore, medicine of the present invention is to be the Chinese patent medicine that feedstock production forms with following pharmaceutical composition:
Radix Ginseng 300-600 weight portion
Rhizoma Chuanxiong 300-600 weight portion
The preferred weight proportioning of pharmaceutical composition of the present invention is:
Radix Ginseng 500 weight portions
Rhizoma Chuanxiong 500 weight portions
Pharmaceutical composition of the present invention can be prepared into any pharmaceutical preparation that is suitable for using clinically according to conventional formulation technology, for example, and tablet, powder, pill, granule, capsule, oral liquid, injection etc.
Pharmaceutical composition of the present invention can directly prepare patent medicine, also can extract respectively each component in the compositions, prepares patent medicine then.These are all within protection scope of the present invention.
The preparation method of medicinal granule of the present invention is:
One, gets the raw materials ready
1, crude drug quality:, differentiate with run-of-the-mill according to pharmacopeia regulation by kind and to check with the medical material of buying.Defective work such as of poor quality, as to go bad, damage by worms, go mouldy must not use.
2, clean: the medical material of discriminating and run-of-the-mill passed examination, carefully examine the removal of impurity.
3, pulverize: Radix Ginseng is broken into the fritter of diameter less than 1cm with Universalpulverizer.
4, weighing: in the prescription ratio, take by weighing Radix Ginseng and Rhizoma Chuanxiong respectively, standby.
Two, extract
1, Radix Ginseng: get and handle clean Radix Ginseng, be ground into coarse powder, take by weighing weight, drop in the multi-functional extractor, the alcohol reflux with 65% three times, 3 hours for the first time by recipe quantity; 2 hours for the second time; 1 hour for the third time; Merge three times backflow, filter, reclaim ethanol to nothing alcohol flavor, cryoconcentration to relative density is the clear paste of 1.20 (80 ℃ of heat are surveyed) again, and is standby.
2, Rhizoma Chuanxiong: the Rhizoma Chuanxiong decoction pieces of the pre-treatment of learning from else's experience, take by weighing weight by recipe quantity, drop in the multi-functional extractor, decoct with water 2.5 hours for the first time three times; 2 hours for the second time; 1.5 hours for the third time; Collect volatile oil (be collected into no volatile oil steam till) with the volatile oil catcher simultaneously.Merge three times decocting liquid, filter, cryoconcentration to relative density is the clear paste of 1.25 (80 ℃ of heat are surveyed), and is standby.After volatile oil separates, in the hermetic container of packing into, standby.
Three, granulate
With Radix Ginseng clear paste and the merging of Rhizoma Chuanxiong clear paste, mixed all even, 1 part of clear paste adds 1.5 parts of sucrose, and 2 parts in dextrin in mixer, is made soft material with an amount of 70% ethanol, and with 12 eye mesh screen granulate, granulate adds Rhizoma Chuanxiong volatile oil simultaneously, thorough mix homogeneously, barrelling sealing.Packing promptly.
The function that pharmaceutical composition of the present invention has benefiting QI for activating blood circulation, nourishes heart and promote blood circulation.Cure mainly the thoracic obstruction, pained of blood stasis due to qi deficiency, be applicable to angina pectoris, diseases such as myocardial infarction.
Prove that through the zoopery pharmacodynamic study pharmaceutical composition of the present invention has following pharmacological action:
1, to the influence of experimental dog myocardial ischemia
Experiment is divided into five groups, matched group and administration two dosage groups, positive drug control group propranolol and diltiazem group.Observation index comprises dog degree of myocardial ischemia, myocardial ischemia scope and myocardial infarct size.The result shows that pharmaceutical composition of the present invention can obviously alleviate epicardial electrogram degree of myocardial ischemia and myocardial ischemia scope, obviously reduces the infarct that shows through N-BT dyeing, acts on similar to beta-blocker propranolol and calcium antagonist diltiazem.
2, dog arteria coronaria side is propped up the circulation influence
Experiment is divided into three groups, matched group, administration group and verapamil group.Observation index comprises that arteria coronaria regurgitation volume, arteria coronaria backflow and presses and arteria coronaria collateral flow amount etc.The result shows, pharmaceutical composition of the present invention can obviously increase the arteria coronaria regurgitation volume, promote side Zhi Xunhuan, and other every indexs are all had better action, and cardiac output is slightly increased, arteria coronaria collateral flow resistance reduces, arteriotony raises, Coronary Perfusion Pressure risings etc. have embodied benefiting QI for activating blood circulation, promote the effect of cardiovascular function.
3, to the influence of partial pressure of oxygen in the dog cardiac muscular tissue
Experiment is divided into three groups, matched group, administration group and verapamil group.Observation index comprises partial pressure of oxygen in shallow-layer and the deep layer cardiac muscular tissue, LC coronary flow.The result confirms that during acute myocardial ischemia, partial pressure of oxygen obviously reduces in deep layer and the superficial layer of myocardium tissue; After the administration; pharmaceutical composition of the present invention can obviously increase partial pressure of oxygen in the deep layer cardiac muscular tissue; and have and increase the interior partial pressure of oxygen trend of superficial layer of myocardium tissue; promote that arteria coronaria side Zhi Xunhuan is open; impel coronary blood flow to distribute again; thereby the oxygen that improves ischemic myocardium is significant for the protection ischemic myocardium for not enough.
4, to the influence of isolated rat heart perfusion
(1) to the influence of normal isolated rat heart.
Experiment is divided into five groups, matched group, three dosage groups of administration group and verapamil group.The result confirms that medicine of the present invention can obviously increase coronary flow, and sustainable 30 minutes, myocardial contraction there is inhibitory action.
(2) to the influence of isolated rat heart ischemia model.
Experiment is divided into matched group, administration group and verapamil group.The result confirms that the hat flow that pharmaceutical composition of the present invention can obviously be alleviated due to the coronary spasm reduces, and suppresses myocardial contraction, reduces cardiac work, conserve energy consumption.
5, to cultivating neonatal rat myocardial cell
45The influence of stream in the Ca.
Experiment is divided into matched group, two dosage groups of administration group and verapamil group.The result confirms that pharmaceutical composition of the present invention can obviously suppress stream in the calcium, and effect obviously.
6, to cultivating the influence of the scarce sugar damage of neonatal rat myocardial cell oxygen consumption and anoxia.
(1) to the influence of oxygen consumption: the trend of the rarely seen slight minimizing myocardial cell oxygen consumption of medicine of the present invention; Can obviously suppress isoproterenol increases the myocardial cell oxygen consumption, and the mechanism that it resists myocardial ischemia is described, part is to act on cellular level.
(2) to cultivating the protective effect of the scarce sugar damage of neonatal rat myocardial cell anoxia: lack myocardial ischemia in the sugar damage analogue body with cultivating the neonatal rat myocardial cell anoxia; the result confirms that medicine of the present invention has direct protective action to this damage; can obviously reduce spilling of LD, this protective effect is relevant with minimizing myocardial cell oxygen consumption.
7, to cultivating the influence of myocardial cell oxygen contradiction, this experiment utilizes after the anoxia again that oxygen supply causes myocardial cell oxygen contradiction damage model, further studies the effect of medicine of the present invention.Behind the myocardial ischemia certain hour, oxygen supply can increase the weight of tissue injury again, i.e. " oxygen contradiction ", result show that damage has significant protective effect to medicine of the present invention to oxygen contradiction on cellular level.
Embodiment
Prescription:
Radix Ginseng 500 grams
Continue 500 grams
Technology:
Crude drug is pulverized after checking, cleaning, and Radix Ginseng is broken into the fritter of diameter less than 1cm with Universalpulverizer.In the prescription ratio, take by weighing Radix Ginseng and Rhizoma Chuanxiong respectively, standby;
Get and handle clean Radix Ginseng, be ground into coarse powder, take by weighing weight, drop in the multi-functional extractor, the alcohol reflux with 65% three times, 3 hours for the first time by recipe quantity; 2 hours for the second time; 1 hour for the third time; Merge three times backflow, filter, reclaim ethanol to nothing alcohol flavor, cryoconcentration to relative density is the clear paste of 1.20 (80 ℃ of heat are surveyed) again, and is standby;
The learnt from else's experience Rhizoma Chuanxiong decoction pieces of pre-treatment takes by weighing weight by recipe quantity, drops in the multi-functional extractor, decocts with water 2.5 hours for the first time three times; 2 hours for the second time; 1.5 hours for the third time; Collect volatile oil (be collected into no volatile oil steam till) with the volatile oil catcher simultaneously.Merge three times decocting liquid, filter, cryoconcentration to relative density is the clear paste of 1.25 (80 ℃ of heat are surveyed), and is standby.After volatile oil separates, in the hermetic container of packing into, standby;
With Radix Ginseng clear paste and the merging of Rhizoma Chuanxiong clear paste, mixed all even, 1 part of clear paste adds 1.5 parts of sucrose, and 2 parts in dextrin in mixer, is made soft material with an amount of 70% ethanol, and with 12 eye mesh screen granulate, granulate adds Rhizoma Chuanxiong volatile oil simultaneously, thorough mix homogeneously, barrelling sealing.Make granule 1000 grams altogether, packing promptly.
Claims (3)
1, a kind of treatment coronary heart disease, anginal Chinese medicine is characterized in that this medicine is the medicament that is prepared from according to following proportioning with Radix Ginseng and Rhizoma Chuanxiong:
Radix Ginseng 300-600 weight portion
Rhizoma Chuanxiong 300-600 weight portion
2, Chinese medicine according to claim 1 is characterized in that the proportioning that the people participates in Rhizoma Chuanxiong is:
Radix Ginseng 500 weight portions
Rhizoma Chuanxiong 500 weight portions
3, according to the Chinese medicine of claim 1 or 2, the dosage form that it is characterized in that this medicine is any in tablet, powder, pill, granule, capsule, oral liquid, the injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97111879 CN1171957A (en) | 1997-06-28 | 1997-06-28 | Drug for curing coronary disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97111879 CN1171957A (en) | 1997-06-28 | 1997-06-28 | Drug for curing coronary disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1171957A true CN1171957A (en) | 1998-02-04 |
Family
ID=5171925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97111879 Pending CN1171957A (en) | 1997-06-28 | 1997-06-28 | Drug for curing coronary disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1171957A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102198162A (en) * | 2011-06-03 | 2011-09-28 | 广东药学院 | Traditional Chinese medicine composition for treating coronary heart disease, and preparation method thereof |
| CN107928677A (en) * | 2017-12-25 | 2018-04-20 | 张新举 | A kind of sole shape harvester and sole shape acquisition method |
| CN110693929A (en) * | 2019-09-09 | 2020-01-17 | 安徽中医药大学 | Application of compound medicine components in treating cerebral infarction recovery period |
-
1997
- 1997-06-28 CN CN 97111879 patent/CN1171957A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102198162A (en) * | 2011-06-03 | 2011-09-28 | 广东药学院 | Traditional Chinese medicine composition for treating coronary heart disease, and preparation method thereof |
| CN102198162B (en) * | 2011-06-03 | 2013-06-19 | 广东药学院 | Traditional Chinese medicine composition for treating coronary heart disease, and preparation method thereof |
| CN107928677A (en) * | 2017-12-25 | 2018-04-20 | 张新举 | A kind of sole shape harvester and sole shape acquisition method |
| CN107928677B (en) * | 2017-12-25 | 2023-09-12 | 张新举 | Sole shape acquisition device and sole shape acquisition method |
| CN110693929A (en) * | 2019-09-09 | 2020-01-17 | 安徽中医药大学 | Application of compound medicine components in treating cerebral infarction recovery period |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1899479A (en) | Chinese medicine compound preparation for treating osteoporosis after menopause and its preparation | |
| CN1245173C (en) | Medicine composition for treating liver fibrillation and liver cirrhosis and its prepn process | |
| CN101041010A (en) | Medicine compound for treating diabetes and its preparation | |
| CN1171957A (en) | Drug for curing coronary disease | |
| CN1742829A (en) | Dripping pill for treating coronary heart disease and preparing method | |
| CN1593489A (en) | Traditional Chinese Medicinal formulation for treating coronary heart disease and preparation method thereof | |
| CN1939410A (en) | Musk medicinal preparation | |
| CN1772119A (en) | Medicine for treating coronary heart disease and angina pectoris and its prepn | |
| CN1107711A (en) | Hypoglycemic compound capsule | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN1218741C (en) | Fingered citron particals for stomach ailment and its preparing method | |
| CN1053111C (en) | Chinese medical composite preparation with such functions as dispelling toxicity, detoxicating, recuperating, health preserving and face nursing | |
| CN1142786C (en) | Medicine for treating coronary heart disease | |
| CN1212143C (en) | Medicine for treating coronary disease and its preparation method | |
| CN1853711A (en) | Xinmaikangzhong Chinese medicinal composition and preparation thereof | |
| CN1282475C (en) | Combination of medication for treating gallbladder disease and preparation method | |
| CN117018156B (en) | Application of astragalus and cassia twig five-substance decoction optimization formula in preparation of drugs for preventing and/or treating cardiotoxicity caused by oxaliplatin | |
| CN100341542C (en) | Compound liver-nourishing ant tablet and bolus | |
| CN1299670C (en) | Capsules for eliminating embolism and their preparation | |
| CN1724054A (en) | Medicinal prepn. for treating hypermenorrhea, and its prepn. method | |
| CN1144123A (en) | Prescription of Xinmaitai and its production process | |
| CN1853696A (en) | Medicine for treating coronary heart disease and preparation thereof | |
| CN1287821C (en) | Combination of medication in use for treating coronary heart disease and preparation method | |
| CN1248722C (en) | Medicine for treating coronary heart disease and preparation method thereof | |
| CN1817355A (en) | Chinese medicinal oral preparation for treating cardiovascular disease and production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |